Reduced-Dose Schedule of Cabazitaxel Viable for Seniors With mCRPC

(MedPage Today) -- A reduced-dose schedule of cabazitaxel (Jevtana) plus prophylactic granulocyte colony-stimulating factor (G-CSF) should be offered to older men with metastatic castration-resistant prostate cancer (mCRPC), according to results...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news